A randomized controlled study of taper-down or abrupt discontinuation of hormone therapy in women treated for vasomotor symptoms

Menopause

Volumn 17, Issue 1, 2010, Pages 72-79

  Lindh Åstrand, Lotta ^a   Bixo, Marie ^b   Hirschberg, Angelica Lindén ^c   Sundström Poromaa, Inger ^d   Hammar, Mats ^a  

^a LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

^b UMEÅ UNIVERSITY   (Sweden)

^c KAROLINSKA INSTITUTE   (Sweden)

^d UPPSALA UNIVERSITY   (Sweden)

Author keywords

Discontinuation of therapy; Health related quality of life (HRQoL); Hormone therapy; Menopause; Vasomotor symptoms

Indexed keywords

ESTRADIOL PLUS MEDROXYPROGESTERONE ACETATE; ESTRADIOL PLUS NORETHISTERONE ACETATE; ESTROGEN; ESTROGEN PLUS PROGESTERONE; TIBOLONE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTHRALGIA; ARTICLE; BREAST CANCER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DEPRESSION; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; ESTROGEN THERAPY; FEMALE; FOLLOW UP; HOT FLUSH; HUMAN; INFECTION; MAJOR CLINICAL STUDY; MULTICENTER STUDY; POSTMENOPAUSE; PSYCHOLOGICAL WELL BEING; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; SLEEP DISORDER; TREATMENT OUTCOME; VAGINAL DRYNESS; VASOMOTOR DISORDER;

DRUG ADMINISTRATION SCHEDULE; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; FEMALE; HOT FLASHES; HUMANS; MENOPAUSE; MIDDLE AGED; PATIENT ACCEPTANCE OF HEALTH CARE; PROGESTERONE; QUALITY OF LIFE; RECURRENCE; SWEDEN;

EID: 74549155060     PISSN: 10723714     EISSN: None     Source Type: Journal    
DOI: 10.1097/gme.0b013e3181b397c7     Document Type: Article

References (40)

1. McKinlay SM, Brambilla DJ, Posner JG. The normal menopause transition. Maturitas 1992;14:103-115.
2. Hammar M, Berg G, Fahraeus L, Larsson-Cohn U. Climacteric symptoms in an unselected sample of Swedish women. Maturitas 1984;6:345-350.
3. Freeman EW, Sherif K. Prevalence of hot flushes and night sweats around the world: a systematic review. Climacteric 2007;10:197-214.
4. Nelson HD. Menopause. Lancet 2008;371:760-770.
5. Avis NE, Ory M, Matthews KA, Schocken M, Bromberger J, Colvin A. Health-related quality of life in a multiethnic sample of middle-aged women: Study of Women's Health Across the Nation (SWAN). Med Care 2003;41:1262-1276.
6. Ledesert B, Ringa V, Breart G. Menopause and perceived health status among the women of the French GAZEL cohort. Maturitas 1994; 20:113-120.
7. Grodstein F, Stampfer MJ, Colditz GA, et al. Postmenopausal hormone therapy and mortality. N Engl J Med 1997;336:1769-1775.
8. Criqui MH, Suarez L, Barrett-Connor E, McPhillips J, Wingard DL, Garland C. Postmenopausal estrogen use and mortality. Results from a prospective study in a defined, homogeneous community. Am J Epidemiol 1988;128:606-614.
9. Cauley JA, Seeley DG, Browner WS, et al. Estrogen replacement therapy and mortality among older women. The study of osteoporotic fractures. Arch Intern Med 1997;157:2181-2187.
10. Hodis HN, Mack WJ, Lobo RA, et al. Estrogen in the prevention of atherosclerosis: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 2001;135:939-953
11. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/ Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial. JAMA 1995;273:199-208.
12. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-333.
13. Herrington DM, Vittinghoff E, Lin F, et al. Statin therapy, cardiovascular events, and total mortality in the Heart and Estrogen/Progestin Replacement Study (HERS). Circulation 2002;105:2962-2967. (Pubitemid 34693827)
14. Pines A, Sturdee DW, Birkhauser MH, Schneider HP, Gambacciani M, Panay N. IMS updated recommendations on postmenopausal hormone therapy. Climacteric 2007;10:181-194. (Pubitemid 46752441)
15. The North American Menopause Society. Estrogen and progestogen use in postmenopausal women: July 2008 position statement of The North American Menopause Society. Menopause 2008;15:584-602.
16. Grady D. A 60-year-old woman trying to discontinue hormone replacement therapy. JAMA 2007;287:2130-2137.
17. Grady D, Ettinger B, Tosteson AN, Pressman A, Macer JL. Predictors of difficulty when discontinuing postmenopausal hormone therapy. Obstet Gynecol 2003;102:1233-1239.
18. Haskell S. After the Women's Health Initiative: postmenopausal women's experiences of discontinuing estrogen replacement therapy. J Womens Health 2004;13:438-442.
19. Ness J, Aronow WS, Beck G. Menopausal symptoms after cessation of hormone replacement therapy. Maturitas 2006;53:356-361.
20. Ockene J, Barad D, Cochrane B, et al. Symptom experience after discontinuing use of estrogen plus progestin. JAMA 2005;294:183-193. (Pubitemid 41043788)
21. Aslan E, Bagis T, Kilicdag EB, Tarim E, Erkanli S, Esra K. How to best discontinue hormone therapy: immediate or tapered? Maturitas 2007;56: 78-83.
22. Haimov-Kochman R, Barak-Glantz E, Arbel R, et al. Gradual discontinuation of hormone therapy does not prevent the reappearance of climacteric symptoms: a randomized prospective study. Menopause 2006;13:370-376. (Pubitemid 43918196)
23. Haimov-Kochman R, Barak-Glantz E, Ein-Mor E, et al. Duration not severity of the climacteric syndrome predicts resumption of hormone therapy after discontinuation: a prospective study. Hum Reprod 2006; 21:2450-2454. (Pubitemid 44530627)
24. Dupuy H. The Psychological General Wellbeing (PGWB) Index. In: Wenger N, Mattson M, Furberg C, Elinson J, eds. Assessment of Quality of Life in Clinical Trials of Cardiovascular Therapies. New York: Le Jacq, 1984:170-183.
25. Wiklund I, Holst J, Karlberg J, et al. A new methodological approach to the evaluation of quality of life in postmenopausal women. Maturitas 1992;14:211-224.
26. Daly E, Gray A, Barlow D, McPherson K, Roche M, Vessey M. Measuring the impact of menopausal symptoms on quality of life. BMJ 1993;307:836-840. (Pubitemid 23281748)
27. Hays J, Ockene JK, Brunner RL, et al. Effects of estrogen plus progestin on health-related quality of life. N Engl J Med 2003;348:1839-1854.
28. Minelli C, Abrams KR, Sutton AJ, Cooper NJ. Benefits and harms associated with hormone replacement therapy: clinical decision analysis. BMJ 2004;328:371.
29. Welton AJ, Vickers MR, Kim J, et al. Health related quality of life after combined hormone replacement therapy: randomised controlled trial. BMJ 2008;337:a1190.
30. Haskell S, Bean-Mayberry B, Gordon K. Discontinuing postmenopausal hormone therapy: an observational study of tapering versus quitting cold turkey: is there a difference in recurrence of menopausal symptoms? Menopause 2009;16:494-499.
31. Kronenberg F. Hot flashes: epidemiology and physiology. Ann N Y Acad Sci 1990;592:52-86; discussion 123-133.
32. Barnabei VM, Grady D, Stovall DW, et al. Menopausal symptoms in older women and the effects of treatment with hormone therapy. Obstet Gynecol 2002;100:1209-1218.
33. Koster A, Eplov LF, Garde K. Anticipations and experiences of menopause in a Danish female general population cohort born in 1936. Arch Women Ment Health 2002;5:9-13.
34. Lindh-Astrand L, Brynhildsen J, Hoffmann M, Hammar M. Vasomotor symptoms usually reappear after cessation of postmenopausal hormone therapyVa Swedish population based study. [published online ahead of print May 15, 2009]. Menopause. doi:10.1097/gme.0b013e3181a53221
35. Rolnick SJ, Kopher RA, DeFor TA, Kelley ME. Hormone use and patient concerns after the findings of the Women's Health Initiative. Menopause 2005;12:399-404.
36. Freedman RR. Laboratory and ambulatory monitoring of menopausal hot flashes. Psychophysiology 1989;26:573-579.
37. Sloan JA, Loprinzi CL, Novotny PJ, Barton DL, Lavasseur BI, Windschitl H. Methodologic lessons learned from hot flash studies. J Clin Oncol 2001;19:4280-4290.
38. Maki PM, Drogos LL, Rubin LH, Banuvar S, Shulman LP, Geller SE. Objective hot flashes are negatively related to verbal memory performance in midlife women. Menopause 2008;15:848-856.
39. Carpenter JS, Monahan PO, Azzouz F. Accuracy of subjective hot flush reports compared with continuous sternal skin conductance monitoring. Obstet Gynecol 2004;104:1322-1326.
40. Norman G, Steiner D. PDQ Statistics, 3rd ed. Hamilton, ON, Canada: BC Decker Inc; 2003.